To evaluate the weight gain after Sibutramine 10 mg daily discontinuation. To evaluate the effect of Sibutramine 10 mg daily in patients who were on a diet for 6 months. DESIGN: After a double-blind, placebo-controlled, parallel, prospective phase for 6 months, the treatments were crossed over and the patients continued in double-blind observation for another 6-month period. SUBJECTS: Forty out of 44 patients who were on Sibutramine and 42a44 who were on placebo switched the trial medication. All the patients were obese at the beginning of the trial (body mass index, BMI b 30 kgam 2 ). During the ®rst phase, the weight loss in the Sibutramine group was 7.52 kg (95% con®dence intervals (95% CI) 6.15; 8.9) and that in the placebo group 3.56 kg (95% CI 2.41; 4.7) (using last observation carried forward (LOCF)). MEASUREMENTS: Body weight, BMI, waist, medical history, assessment of hunger, satiety and diet compliance, standard laboratory assessments, blood pressure, heart rate and ECG. RESULTS: Thirty out 40 patients in the Sibutramineaplacebo (SaP) group and 32 out of 42 in the placeboaSibutramine (PaS) group completed the second phase of the trial. During the second part of the trial the SaP gained 3.21 (95% CI 2.15; 4.26) kg,
Introduction
A minimal weight loss induces signi®cant health bene®ts in obese patients. 1 The ultimate goal of the treatment of obesity is to decrease the risks associated with the disease by means of long-term weight loss maintenance, 2 but the maintenance of weight loss is very dif®cult and most of the patients tend to regain weight. 3, 4 The recognition of this problem has led to an approach of long-term treatments for obesity, including drug therapy, in a similar way to other chronic diseases. 2, 3, 5 Sibutramine is a brand-new agent for weight loss and weight loss maintenance. Sibutramine is a serotonin and noradrenaline reuptake inhibitor with no effect on the dopamine reuptake system, 6 and has no addictive potential. 7, 8 Animal studies show that Sibutramine induces weight loss by enhancing satiety and increasing the metabolic rate. 6, 9 Three clinical trials of the effect of Sibutramine have been extensively reported up to this moment. Weintraub et al reported a dose-dependent weight loss induced by Sibutramine over 8 weeks of treatment; the weight loss achieved was 3% for the 5 mg group and 5.1% in the 20 mg group. 10 In a monocenter trial, Bray et al 11 found that Sibutramine produced dose dependent weight loss in obese patients over a 24 week period, with doses ranging from 5 to 30 mg. The weight loss was 3 ± 9% of the baseline body weight and 28 ± 62% of the patients lost at least 5% of the initial body weight. The reported adverse events were dry mouth, anorexia, constipation and insomnia, and were also dose-dependent. The ®ndings were con®rmed by a multicenter trial which included these previous results. 12 Hanotin et al described another dose range study for 12 weeks with similar results. Weight loss was dose-dependent. The proportions of patients achieving a weight loss of at least 5% of their initial body weight were 23% for 5 mg, 49% for 10 mg and 55% for 15 mg. The adverse events associated with Sibutramine were dry mouth, insomnia and constipation, and were more frequent in the 15 mg group. 13 A Mexican trial comparing Sibutramine 15 mg vs placebo in a double-blind model found (using the method of last observation carried forward) that weight loss in the Sibutramine group was 10.27 kg (95% CI 7.66; 13.07), corresponding to 11.8% of the initial body weight, and 37a51 (72.55%) patients losing at least 5% of the initial body weight. The most frequent adverse events were upper respiratory tract infections and constipation.
14 Antiobesity drugs induce weight loss by the ®rst 6 months of treatment and then reach a plateau. 5, 15 After this weight loss period patients on drug treatment tend to gain weight, 15, 16 but in the case of Sibutramine 11,12 most of the weight loss is maintained for at least 1 y.
After the drug discontinuation, patients tend to gain weight, and it must be considered as evidence of the ef®-cacy. 2, 17 This weight gain was observed after the discontinuation of Sibutramine. 12 The aim of the second phase of the trial, after cross-over, was to study the effect of Sibutramine withdrawal under placebo-controlled conditions and to explore the adverse events presented after stopping Sibutramine and, additionally, the effect of Sibutramine in patients who had been on diet for 6 months.
During the ®rst phase of this trial 109 obese patients (body mass index, BMI b 30 kgam 2 ) from 16 to 65 y received in double-blind Sibutramine 10 mg or a matching placebo, once a day, per os (by mouth), over a period of 6 months. Forty out of 55 patients in the Sibutramine group and 44 out of 54 patients in the placebo group completed the trial. Using the method of last observation carried forward (LOCF), the weight loss in the Sibutramine group was 7.52 kg (95% con®dence intervals (95% CI) 6.15; 8.9) and 3.56 kg (95% CI 2.41; 4.7) in the placebo group (P`0.05 by paired Student's t-test). Thirty two Sibutramine patients had 45 adverse events; the most frequent adverse events in the Sibutramine group were dry mouth (n 19), increase in blood pressure (n 5), constipation (n 5) and tachycardia (n 5); 23 placebo patients had 29 adverse events, mainly increase in blood pressure (n 11) and dry mouth (n 10). Two Sibutramine patients withdrew the trial due to adverse events.
The second phase of the trial consisted of an additional 6 month period of treatment after a treatment cross-over. Only patients who entered the second phase are considered.
Patients and methods
A double-blind, cross-over, placebo-controlled, parallel group, prospective clinical trial was conducted in order to assess the safety and ef®cacy of Sibutramine in the treatment of obesity in Mexican patients. The ®rst phase of the trial was reported in International Journal of Obesity and Related Diseases. The second phase of the trial after the cross-over is reported here; only the patients who entered the second phase are considered.
Male and female patients from 16 to 65 y with a BMI greater than 30 kgam 2 were recruited after written informed consent had been obtained. The following patients were not included in the trial: those suffering from endocrine diseases other than type 2 diabetes mellitus, uncontrolled hypertension, autoimmune diseases, ischemic heart disease, arrhythmia, lactating or pregnant women, psychosis, and those requiring drugs acting on the central nervous system, cathartics, thyroid replacement or diuretics.
Patient participation was stopped if they became pregnant, presented with a concomitant severe disease, suffered severe adverse events, withdrew their informed consent or failed to attend the clinical appointments. The subjects were outpatients attending to the Endocrinology Service, Hospital General de Me Âxico.
Patients were randomized either to the group taking Sibutramine 10 mg once a day, per os or to the group taking placebo in the same way. In order to randomize the participants, we prepared a computer list of 120 random numbers in 12 different blocks of 10. For each block the proportion of evenaodd numbers by group was 3a2 or 2a3, with no more than three consecutive positions. The patients were assigned a consecutive number as they completed the initial laboratory safety test and an electrocardiogram to con®rm the selection criteria. For each number there was a box containing 19 packages with 10 capsules each (two blisters of ®ve capsules), and an opaque sealed envelope with the drug code; all the materials for a patient were identi®ed by the patient number. The materials were prepared by AB, who did not know the identity of the patients. GF received the trial materials without any knowledge of the procedures or order in the random number list.
The ®rst patient entered the trial by March 1998 and the last patient ®nished the second phase by July 1999.
The appearances of the boxes, packages, blisters and capsules were the same.
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Patients were recommended to complete a diet of 30 kcalakg of the ideal body weight, the diet should have about 50% of the energy from carbohydrates, 30% from lipids and 20% from proteins. Patients received a list of recommended food portions and the possible combinations.
Patients received the dietetic advice 15 days before the beginning of the study medications and the dietetic supervision during the treatment phase of the trial.
Clinical control visits were 15 days before the beginning of the study medication, when the study medication began, and then monthly, up to 6 months of treatment. When the patients had completed 6 months of treatment, those taking Sibutramine switched to placebo and vice versa. Patients visited the investigators monthly to assess the end-points and check the safety, up to the end of the second phase. The ancillary therapy remained the same during the second phase of the trial.
The primary end-points for the trial were the body weight and BMI, the secondary end-points were the waist and waista hip ratio. Appetite, satiety and diet adherence were also evaluated. For appetite, the visual analog scale was a line of 155 mm with 10% divisions from 0% with the quotatioǹ very hungry' on the left, up to 100%`without hunger' to the right. In the case of satiety the scale was similar but the 0% mark on the left corresponded to the legend`extremely full' and the right mark of 100% to`emptiness sensation'. The scale for compliance with the diet had the legend`impossible to follow' corresponding to 0% on the left and`easy to comply' on the right mark of 100%. All the described parameters were evaluated at each visit.
Adverse events were reported as they were detected. Patients were encouraged to call the investigators if they had any question or complaint at any time. Additionally, the patients were asked if`something unusual had happened since your last visit' in all the visits, in order to collect any possible complaints.
Blood cytology, blood chemistry and urinalysis were performed before the beginning of the medication and after 6 and 12 months of medication. Electrocardiograms were performed at these times too.
The proposed statistical analysis for the end-points included the intragroup comparison of the values at the baseline with those in the last visit by the paired Student's t-test. The same kind of analysis was performed with the last observation carried forward (LOCF) of the end-points, where the last observation replaced the missing values. For this analysis, only patients who completed at least 1 month of treatment during the second phase with the corresponding end-point evaluation were considered. Only the data of the patients completing the ®rst phase are considered.
For the rest of the interval measurements, the intragroup comparisons were tested by the paired Student's t-test, while the intergroup comparisons were performed using the unpaired Student's t-test, and in the case of nominal scales in the intergroup comparisons, the w 2 test, with continuity correction in the 2Â2 tables, were used. 
Results
Forty patients in the group SaP (Sibutramineaplacebo) and 44 in the group PaS (placeboaSibutramine) ®nished the ®rst phase of treatment. Forty patients in the group SaP and 42 in the group PaS initiated the second phase of the trial. One patient in the group PaS experienced an adverse event when she switched to Sibutramine and withdrew the trial; this case is taken into account for safety analysis but not for the ef®cacy analysis.
The characteristics of the patient at the beginning of the second phase are shown in Table 1 . Evolution of the endpoints throughout of the trial is shown in Table 2 for completers and Table 3 for last observation carried forward (LOCF).
The endpoint differences regarding the values after the end of the ®rst phase are shown in Table 4 . Patients who changed from Sibutramine to placebo presented a weight gain, while those who switched from placebo to Sibutramine lost weight.
The evolution of percentage of baseline weight and waist during the ®rst and second phase of the study are shown in Figures 1 and 2 . Only the patients starting the second phase were considered and the LOCF values were used for the second phase.
By the end of the ®rst phase of the trial 33a40 (82.5%) patients in the group SaP had achieved a signi®cant weight loss ! 5% of baseline body weight, while only 20a41 (48.8%) in the group PaS reached that goal.
After crossing 34a40 (85%) the patients in group SaP increased their body weight, and 32a41 (78%) group PaS patients loss weight; 24a41 (58.5%) lost`5% and 8a41 (19.5%) from 5 to 10% (regarding the weight at the end of the ®rst phase). So, by the end of the second phase 21a40 Second phase of Sibutramine trial G Fangha Ènel et al (52.5%) patients in the group SaP had lost ! 5% of the baseline body weight and this goal was achieved by 25a41 (61%) patients in the group PaS. The changes in both periods are shown in Figure 3 .
The mean values for the parameters appetite, satiety and adherence to the recommended diet (as marked on visual analog scale) were evaluated too. After cross-over the patients in the group SaP presented signi®cant increase in appetite as well as a signi®cant decrease in the diet adherence (except in the month 10). In this group the satiety level decrease signi®cantly in the months 8 and 11. Meanwhile, the patients in the group PaS had decreased appetite in months 8 and 12, increase in the satiety in month 8, and better diet adherence during months 7 and 8.
Regarding the systolic blood pressure, no signi®cant changes were found in the group SaP, instead the group PaS had signi®cant, but small, increases in months 8 and 11 (115.7 AE 7.5 by month 6 vs 118.3 AE 6.6 and 120.5 AE 9.7 respectively; P`0.05 by paired Student's t-test). No signi®-cant changes in diastolic blood pressure were found in both groups.
Group SaP patients had minimal, but signi®cant decrease in heart rate in months 8 and 9 (75.9 AE 4.4 by month 6 vs 74.2 AE 3.4 and 74.1 AE 3.3, respectively; P`0.05 by paired 
-test).
During the second phase of the trial four patients in group SaP presented ®ve episodes of clinically signi®cant increase of blood pressure (systolic ! 140 andaor diastolic ! 90 mmHg). Only one patient received an antihypertensive drug (lisinopril) to control blood pressure. On the other hand, four patients in group PaS had six episodes of clinically signi®cant increase of blood pressure, but none of them required antihypertensive medication. Only two patients in group PaS presented transitory heart rate ! 90 bpm, and they did not require any speci®c treatment. When baseline and Table 5 . Patients in group SaP had lower cholesterol levels by the end of the ®rst phase and they had persistent decrease in triglycerides and LDL with a concomitant increase in HDL by the end of ®rst and second phase. Patients in group PaS only had HDL increase after the end of the second phase.
Eleven patients in the group SaP suffered 14 adverse events, the most common event being blood pressure increase (four cases). Nineteen patients in the group PaS had 29 adverse events, the most common events being dry mouth (eight cases), constipation (®ve cases) and blood pressure increase (four cases, including one case with associated increase in heart rate). The complete list of adverse events is given in Table 6 . Seven patients in the group SaP were lost to follow-up and three retracted their informed consent. In group PaS one patient withdrew due to an adverse event (generalized itching and chills), four were lost to follow-up and ®ve retracted their informed consent.
Discussion
In this second phase the two groups are not themselves comparable, but the model provides important clues on obese patient behavior on Sibutramine treatment.
In this trial the cross-over design allows different scenarios to be evaluated in the current consultation: what happened if a patient, who had been on diet and exercise for several months was treated with Sibutramine? Was there a weight rebound after treatment with Sibutramine? Is there any compulsion to continue Sibutramine after treatment?
The response of the patients who were in the placebo group was much less important than that observed if the patients had just begun Sibutramine after a brief run-in period. During the second phase the patients in the group PaS achieved a 2% weight loss compared with the end of the ®rst phase (only eight out of 41 (19.5%) patients had weight loss between 5 and 10%), instead the patients in the group SaP had achieved a weight loss of about 10% when the ®rst phase ®nished (15a40 (37.5%) had a weight loss from 5 to 10%, and 18a40 (45%) ! 10%); meanwhile, nine out of 41 (21.9%) patients in group PaS experienced weight gain during the second phase.
Both groups of patients had about 6% weight loss regardless the treatment order; the weight changes were very small after the treatment cross-over. Yet the patients in the SaP group had persistent bene®ts on the HDL, LDL and triglyceride levels in contrast to the patients in the PaS group, who only presented an increase in HDL concentration after the cross-over.
The bene®ts of the weight reduction produced by Sibutramine, during the treatment and after it, should be evaluated in patients suffering co-morbidities such as hypertension and diabetes.
It is important to note that patients in the PaS had reached a weight loss plateau and even had begun to gain weight during the ®rst phase of the trial and probably had resistance to weight loss. On the other hand, patients with 1 month on a very low caloric diet and then treated with Sibutramine, 10 mg daily for 1 y, had a weight loss of 5.2 AE 7.5 kg. 18 Resistance to weight loss and weight rebound after 6 months of continuous pharmacotherapy has been described. 2, 15, 17 This resistance to weight loss may be ascribed to the reduction in the resting metabolic rate. 19, 20 Some authors have found that Sibutramine prevents the decline in energy expenditure that follows weight loss. 21, 22 This effect may explain the weight loss maintenance during long-term Sibutramine treatment 11, 12 and the effect of Sibutramine in the diet-patients who were in a weight plateau.
Thirty-four out of 40 (85%) patients presented weight gain in group SaP, but this weight loss did not reach the baseline levels. Weight gain after the discontinuation of Sibutramine has been described previously. 12 This weight gain must be considered as evidence of the effect of the drug in weight loss maintenance. 2, 17 Patients in group PaS presented good tolerance to the Sibutramine treatment; only one patient withdrew the trial because of adverse events.
Patients in the group SaP had no important complaints when they switched to placebo, and none requested open administration of Sibutramine. This observation is compatible with studies that showed the low abuse potential of Sibutramine. 7, 8 We conclude that after Sibutramine discontinuation there is weight gain in most the patients, but it does not reach the previous baseline body weight. These results stress the need for long-term pharmacotherapy as well as the convenience 
